Human pharmacology of the methamphetamine stereoisomers

Clinical Pharmacology and Therapeutics

Volumn 80, Issue 4, 2006, Pages 403-420

  Mendelson, John ^a   Uemura, Naoto ^a   Harris, Debra ^a   Nath, Rajneesh P ^a   Fernandez, Emilio ^a   Jacob III, Peyton ^a   Everhart, E Thomas ^a   Jones, Reese T ^a  

^a CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE; METHAMPHETAMINE; PLACEBO;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD PRESSURE; BREATHING RATE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; ENANTIOMER; HEART RATE; HUMAN; MALE; PRIORITY JOURNAL; RACEMIZATION; RATING SCALE; STEREOISOMERISM; VISUAL ANALOG SCALE;

ADULT; AMPHETAMINE-RELATED DISORDERS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; BLOOD PRESSURE; CENTRAL NERVOUS SYSTEM STIMULANTS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; HALF-LIFE; HEART RATE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; METHAMPHETAMINE; RESEARCH DESIGN; RESPIRATION; STEREOISOMERISM;

EID: 33749267275     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clpt.2006.06.013     Document Type: Article

References (49)

1. Logan B.K. Methamphetamine-effects on human performance and behavior. Forensic Sci Rev 14 (2002) 134-151
2. Butterfield F. States may restrict cold pills with ingredient in Meth. The New York Times 2005 Jan 30; Sect. 1:1.
3. Peters F.T., Kraemer T., and Maurer H.H. Drug testing in blood: validated negative-ion chemical ionization gas chromatographic-mass spectrometric assay for determination of amphetamine and methamphetamine enantiomers and its application to toxicology cases. Clin Chem 48 (2002) 1472-1485
4. Moore K.A., Ismaiel A., and Poklis A. α-Benzyl-N-methylphenethylamine (BNMPA), and impurity of illicit methamphetamine synthesis: III. Detection of BNMPA and metabolites in urine of methamphetamine users. J Anal Toxicol 20 (1996) 89-92
5. Mendelson J., Jones R., Upton R., and Jacob III P. Methamphetamine and ethanol interactions in humans. Clin Pharmacol Ther 57 (1995) 559-568
6. Cook C.E., Jeffcoat A.R., Hill J.M., Pugh D.E., Patetta P.K., Sadler B.M., et al. Pharmacokinetics of methamphetamine self-administered to human subjects by smoking S-(+)-methamphetamine hydrochloride. Drug Metab Dispos 21 (1993) 717-723
7. Alles G.A. The comparative physiological actions of dl-beta-phenylisopropylamines. J Pharmacol Exp Ther 47 (1933) 339-354
8. Alles G.A. Comparative actions of optically isomeric phenylisopropylamines. J Pharmacol Exp Ther 66 (1939) 1
9. Blascho H. Amine oxidase and benzedrine. Nature 145 (1940) 26-27
10. van Kammen D.P., Ninan P.T., and Hommer D. Amphetamine enantiomers: psychopharmacological effects. In: Smith D.F. (Ed). CRC handbook of stereoisomers: drugs in psychopharmacology (1984), CRC Press, Boca Raton (FL) 297-315
11. Morgan J.P. The clinical pharmacology of amphetamine. In: Smith D.E., Wesson D.R., Buxton M.E., Seymour R.B., Ungerleider J.T., Morgan J.P., et al. (Eds). Amphetamine use, misuse, and abuse: proceedings of the National Amphetamine Conference, 1978 Vol 3 (1979), G. K. Hall, Boston 3-10
12. Rothman R.B., Baumann M.H., Dersch C.M., Romero D.V., Rice K.C., Carroll F.I., et al. Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse 39 (2001) 32-41
13. Rothman R.B., and Baumann M.H. Monoamine transporters and psychostimulant drugs. Eur J Pharmacol 479 (2003) 23-40
14. Vree T.B. Pharmacokinetics and metabolism of amphetamines (1973), Catholic University of Nijmegen, Nijmegen [PhD dissertation]
15. Beckett A.H., and Shenoy E.V.B. The effect of N-alkyl chain length and stereochemistry on the absorption, metabolism and urinary excretion of N-alkylamphetamines in man. J Pharm Pharmacol 25 (1973) 793-799
16. Hutchaleelaha A., and Mayersohn M. Influence of activated charcoal on the disposition kinetics of methamphetamine enantiomers in the rat following intravenous dosing. J Pharm Sci 85 (1996) 541-545
17. Rowland M., and Beckett A.H. The amphetamines: clinical and pharmacokinetic implications of recent studies of an assay procedure and urinary excretion in man. Arzneimittelforschung 16 (1966) 1369-1373
18. Jirovský D., Ševčík J., Andarová Z., Smysl B., Barták P., Bedná øP., et al. The pilot study of methamphetamine enantiomer metabolism in man by capillary electrophoresis. Chemica 40 (2001) 25-34
19. Gunne L.M., and Anggard E. Pharmacokinetic studies with amphetamines-relationship to neuropsychiatric disorders. J Pharmacokinet Biopharm 6 (1973) 481-495
20. McNair D., Lorr M., and Droppleman L.F. EdITS manual for the Profile of Mood States (POMS) (1992), Educational and Industrial Testing Service, San Diego
21. Beck A.T., Ward C.H., Mendelson M., Mock J., and Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry 4 (1961) 53-63
22. Spielberg C.D., Gorsuch R.L., and Lushene R.E. Manual for the State-Trait Anxiety Inventory (Form X) (self-evaluation questionnaire) (1970), Consulting Psychologists Press, Palo Alto
23. Buss A.H., and Durkee A. An inventory for assessing different kinds of hostility. J Consult Psychol 21 (1957) 343-349
24. Cook C.E., Jeffcoat A.R., Sadler B.M., Hill J.M., Voyksner R.D., Pugh D.E., et al. Pharmacokinetics of oral methamphetamine and effects of repeated daily dosing in humans. Drug Metab Dispos 20 (1992) 856-862
25. Driscoll R.C., Barr F.S., Gragg B.J., and Moore G.W. Determination of therapeutic blood levels of methamphetamine and pentobarbital by GC. J Pharm Sci 60 (1971) 1492-1495
26. Perez-Reyes M., White W.R., McDonald S.A., Hicks R.E., Jeffcoat A.R., Hill J.M., et al. Clinical effects of daily methamphetamine administration. Clin Neuropharmacol 14 (1991) 352-358
27. Perez-Reyes M., White W.R., McDonald S.A., Hill J.M., Jeffcoat A.R., and Cook C.E. Clinical effects of methamphetamine vapor inhalation. Life Sci 49 (1991) 953-959
28. Schepers R.J., Oyler J.M., Joseph Jr. R.E., Cone E.J., Moolchan E.T., and Huestis M.A. Methamphetamine and amphetamine pharmacokinetics in oral fluid and plasma after controlled oral methamphetamine administration to human volunteers. Clin Chem 49 (2003) 121-132
29. Shappell S.A., Kearns G.L., Valentine J.L., Neri D.F., and DeJohn C.A. Chronopharmacokinetics and chronopharmacodynamics of dextromethamphetamine in man. J Clin Pharmacol 36 (1996) 1051-1063
30. Harris D., Baggott M., Welm S., Jacob III P., Mendelson J., Jones R., et al. Pharmacokinetic and dynamic effects of MDMA in humans. [abstract]. Clin Pharmacol Ther 67 (2000) 112
31. Modi N.B., Wang B., Noveck R.J., and Gupta S.K. Dose-proportional and stereospecific pharmacokinetics of methylphenidate delivered using an osmotic, controlled-release oral delivery system. J Clin Pharmacol 40 (2000) 1141-1149
32. Harris D.S., Boxenbaum H., Everhart E.T., Sequeira G., Mendelson J.E., and Jones R.T. The bioavailability of intranasal and smoked methamphetamine. Clin Pharmacol Ther 74 (2003) 475-486
33. Nagai T., Matsushima K., Nagai T., Yanagisawa Y., Fujita A., Kurosu A., et al. Interpretation and enantiomer analysis of methamphetamine abusers' urine and illegally brewed methamphetamine crystals. J Anal Toxicol 24 (2000) 140-145
34. Riviere G.J., Gentry W.B., and Owens S.M. Disposition of methamphetamine and its metabolite amphetamine in brain and other tissues in rats after intravenous administration. J Pharmacol Exp Ther 292 (2000) 1042-1047
35. Yu Q., Larson D.F., and Watson R.R. Heart disease, methamphetamine and AIDS. Life Sci 73 (2003) 129-140
36. McKenna D.J., Guan X.M., and Shulgin A.T. 3,4-Methylenedioxyamphetamine (MDA) analogues exhibit differential effects on synaptosomal release of 3H-dopamine and 3H-5-hydroxytryptamine. Pharmacol Biochem Behav 38 (1991) 505-512
37. Cooper J., Bloom F., and Roth R.H. Dopamine. In: Cooper J.R., Bloom F.E., and RH R. (Eds). The biochemical basis of neuropharmacology. 8th ed. (2003), Oxford University Press, New York 225-270
38. Koob G.F. Drugs of abuse: anatomy, pharmacology and function of reward pathways. Trends Pharmacol Sci 13 (1992) 177-184
39. Kuczenski R. Biochemical actions of amphetamine and other stimulants. In: Creese I. (Ed). Stimulants: neurochemical, behavioral and clinical perspectives (1983), Raven Press, New York 31-61
40. McGregor A., and Roberts D. Mechanisms of abuse. In: Cho A., and Segal D. (Eds). Amphetamine and its analogs: psychopharmacology, toxicology, and abuse (1994), Academic Press, New York 243-266
41. Kuczenski R., Segal D.S., Cho A.K., and Melega W. Hippocampus norepinephrine, caudate dopamine and serotonin, and behavioral responses to the stereoisomers of amphetamine and methamphetamine. J Neurosci 15 (1995) 1308-1317
42. Glaser P.E., Thomas T.C., Joyce B.M., Castellanos F.X., and Gerhardt G.A. Differential effects of amphetamine isomers on dopamine release in the rat striatum and nucleus accumbens core. Psychopharmacology (Berl) 178 (2005) 250-258
43. Harris D.S., Reus V.I., Wolkowitz O.M., Mendelson J.E., and Jones R.T. Altering cortisol level does not change the pleasurable effects of methamphetamine in humans. Neuropsychopharmacology 28 (2003) 1677-1684
44. Harris D.S., Baggott M., Mendelson J.H., Mendelson J.E., and Jones R.T. Subjective and hormonal effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacology (Berl) 162 (2002) 396-405
45. Liechti M.E., and Vollenweider F.X. The serotonin uptake inhibitor citalopram reduces acute cardiovascular and vegetative effects of 3,4-methylenedioxymethamphetamine ('Ecstasy') in healthy volunteers. J Psychopharmacol 14 (2000) 269-274
46. Liechti M.E., Saur M.R., Gamma A., Hell D., and Vollenweider F.X. Psychological and physiological effects of MDMA ("Ecstasy") after pretreatment with the 5-HT(2) antagonist ketanserin in healthy humans. Neuropsychopharmacology 23 (2000) 396-404
47. National Drug Intelligence Center. Effects of Oklahoma pseudoephedrine law realized immediately. Narcotics Digest Weekly 3 28 (2004) 2
48. National Drug Intelligence Center. Asia-produced pseudoephedrine increasingly used in superlabs. Narcotics Digest Weekly 3 28 (2004) 3
49. Cunningham J.K., and Liu L.M. Impacts of federal ephedrine and pseudoephedrine regulations on methamphetamine-related hospital admissions. Addiction 98 (2003) 1229-1237